Patient Preference Evidence Generation

ROLE SUMMARY

Patient preferences have an increasingly important role in healthcare decision making. Health authorities and HTA bodies are encouraging companies include patients in drug development and to provide evidence of the patient perspective on the benefit, risk, and value of their products. Evidence of preference heterogeneity can be used to encourage and guide shared clinical decision making.  The Patient Preference Evidence Generation is responsible developing and using the patient preference capabilities across the enterprise to support patient-centered decision making related to Pfizer IM/I&I assets among external stakeholders including Health Authorities, Health Technology Assessors, healthcare providers, and policy makers, among others. The PPEG for IM/I&I will oversee patient preference evidence generation activities and ensure excellence in the development and use of patient preference information to support external decision making related to pipeline and inline IM/I&I products and programs.

ROLE RESPONSIBILITIES

• Provide expert support and leadership to IM and I&I asset teams in the design and execution of fit-for purpose preference studies (including patient preference studies (PPS),HCP preference studies and other stakeholder preference studies).
• Champion inclusion of the preference data in evidence generation activities across the life cycle of all IM and I&I assets.
• Lead the development of preference data as evidence to demonstrate the value of Pfizer IM and I&I products to external stakeholders (Health Authorities, HTA Bodies, Payers, Healthcare Providers, etc.).
• Collaborate with IM and I&I evidence generation planning teams to include preference studies in Integrated Evidence Planning.
• Lead preference data generation activities to support categories of IM and I&I assets (including, for example assessments of unmet need, adverse event indices, and drug product formulations).
• Develop and implement innovative uses of omnichannel dissemination vehicles for increasing the impact of Pfizer-sponsored preference studies.
• Participate actively in preference study governance, educational, and information-sharing activities through leadership in the PPS  Technical Advisory Committee, the PPS Community of Practice and internal and external presentations.
• Participate actively in interactions with regulators, HTA bodies and other external decision makers related to IM/I&I preference studies.
• In conjunction with other members of the Patient Preference Integration team, track changes in external best-practice guidance (e.g., ICH, IMI/IHI, ISPOR and other guidances) and implement recommendations and guidelines in the conduct of patient preference studies as appropriate.
• In conjunction with other members of the Patient Centered Research and Partnerships team, support interactions with patient groups and include patients as partners in research.
• Develop tools, templates, job aids, slide presentations, and other materials as necessary to educate colleagues on good PPS research practices, to increase efficiency in project execution, and to assist colleagues in the conduct of the PPS wherever possible.
• Use AI and LLM tools to increase efficiency in preference evidence generation while maintaining superior quality of Pfizer preference studies.
• Develop and implement metrics to track progress and impact of preference evidence generation activities and initiatives.
• Participate regularly in research with intent to publish.

BASIC QUALIFICATIONS

• Advanced degree, including MS, MA, PhD or equivalent qualifications in a field related to quantitative preference elicitation including, but not limited to, economics, statistics, decision science, survey research methods, and epidemiology.
• At least 10 years’ experience hands-on expertise with a BS/BA, 8 years’ experience with an MBA/MS, 6 years’ experience with a PhD.
• In-depth knowledge of Preference Elicitation methods including, but not limited to discrete choice experiments, best-worst scaling, threshold techniques, swing weighting, and direct elicitation
• A proven publication record
• Knowledge of pharmaceutical clinical, commercial, regulatory, and competitive issues as well as relevant Health Authority guidelines.
• Ability to establish a vision and obtain buy-in and endorsement from cross-functional parties across the lifecycle
• Strong situational leadership skills & the ability to lead through influence in cross-functional & highly matrixed teams
• Proven ability to lead teams, build coalitions and develop strong partnerships across disciplines and geographies in a matrix environment to optimize the function’s performance and contribution.          
• Excellent cus